Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity

Tofactinib is a JAK inhibitor approved for ulcerative colitis in humans. Despite of its’ proven effectiveness in humans, mechanistic data are scarce on the effectiveness of Tofactinib in experimental colitis in mice. We induced experimental colitis by transfer of CD4+CD25− isolated T cells into RAG2...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramanyam, Sudheendra Hebbar, Hriczko, Judit Turyne, Pappas, Angeliki, Schippers, Angela, Wagner, Nobert, Ohl, Kim, Tenbrock, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992375/
https://www.ncbi.nlm.nih.gov/pubmed/36882462
http://dx.doi.org/10.1038/s41598-023-30616-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992375/
https://www.ncbi.nlm.nih.gov/pubmed/36882462
http://dx.doi.org/10.1038/s41598-023-30616-w

Ejemplares similares